| Revenue growth | FY26 up 37.1% YoY; Q4 up 134.9% YoY. |
|---|---|
| Margins | Record Q4 EBITDA margin 40.5%; FY26 margin 29.4%. |
| Order book | CMS contributed over two-thirds of Q4 revenue. |
| Demand visibility | Strong pipeline visibility; peptide projects ramping up. |
| Management confidence | High confidence in long-term visibility anchored by commercial molecules. |
Growth
Q4 revenue grew 134.9% YoY to ₹788.7cr; FY26 revenue up 37.1% to ₹2053.1cr; FY26 PAT rose to ₹363.1cr.
Outlook
Aspirational 18-20% CAGR; peptide facility operational by July 2026; ₹397.1cr capex spent in FY26.
Risks
Business lumpiness, raw material price volatility, geopolitical risks in Middle East, and potential moderation of ROCE.
Earnings Call filed with BSE, NSE: NEULANDLAB. Summary written with AI assistance from the document.
Neuland Laboratories Ltd: key numbers
- Share price
- ₹21,890.00
- Market cap
- ₹28,085 Cr
- Revenue (annual)
- ₹2,023 Cr
- Net profit (annual)
- ₹364.0 Cr
- P/E (TTM)
- 56.4×Sector 50.4×
- Promoter holding
- 32.62%-0.01% QoQ
- FII holding
- 21.08%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Neuland Laboratories Ltd
All →Neuland Laboratories Production Started
Neuland commissioned its first commercial peptide manufacturing module with 7,000L reactor capacity. Module two expansion is underway to meet rising customer demand for peptide APIs.
- peptide manufacturing reactor capacity
- 7000 L
Neuland Laboratories Capacity Expansion: ₹126 Cr Investment
Neuland Laboratories' board approved ₹126 Crore capex to acquire 134 acres of land in Andhra Pradesh for future expansion. The company holds ROFR on additional land.
- Value
- ₹126.0 Cr
- land acquisition
- 134.0 acres
Neuland Laboratories Earnings Call Transcript: Key Takeaways
Q1FY27 was broadly in line with expectations, showing strong YoY revenue and profit growth. Management remains confident in achieving a 20% growth rate despite inherent quarterly volatility in the CMS business.
- Call
- Guides 20% growth
Neuland Laboratories Investor Presentation: Key Takeaways
Neuland reported Q1FY27 total income of ₹650.1 Cr (116.3% YoY growth) with an EBITDA margin of 35.5%. Growth is driven by the CMS business and commercial molecules.
Neuland Laboratories Q1 FY27 Results: Net Profit ₹147.7 Cr, Up 962.6% YoY
Neuland Laboratories Ltd reported revenue from operations of ₹641.6 Cr (+119.1% YoY) and net profit of ₹147.7 Cr (+962.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹147.7 Cr · +962.6% YoY
Neuland Laboratories Earnings Call: Key Takeaways
Neuland Laboratories' March 2026 API Product List showcases a robust portfolio across diverse therapeutic segments including anticoagulants, antipsychotics, and peptides.